In 2016, AMCP made pre-approval information exchange (PIE) a legislative priority recognizing its vital importance to patients. On June 8, 2022, the U.S. House of Representatives passed the PIE Act of 2022. Learn more about PIE as a legislative priority for AMCP.
Prescription digital therapeutics are software programs that physicians prescribe as a form of treatment. They can help patients manage serious conditions ranging from opioid addiction to asthma to sleep disorders.
During the COVID-19 crisis, managed care professionals are facing unique challenges to deliver patient care. This resource center is designed to aggregate timely information for AMCP members and stakeholders.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
